I've got no issues with it. Just another way to saying that...

I've got no issues with it. Just another way to saying that we've got Patient 1 out of 240.

Management have earmarked this a significant milestone - given they previously tied it to performance. But the market volume was very low, which points to a lack of interest, the long horizons of biotech, lack of publicising or to a lack of capital in the markets.

From my perspective, management keeps hitting their goals. When it comes to selling the business, they will sell at a price that is adjusted to real term inflation. For me now, this therefore represents the best and also most defensive asset to hold in this market with the threat of stagflation and years of high inflation ahead
.